Global Muscle Relaxant Drug Market Key Impacting Factors

The global muscle relaxant drug market is projected to grow at a significant CAGR during the forecast period. The key factors that drive the global market growth include the rising number of geriatric populations, increased number of surgeries, approvals of new label indications, and rapid innovations. Baclofen, dantrolene, and tizanidine are among the three muscle relaxants approved by the FDA to treat spasticity. Whereas, methocarbamol, metaxalone, carisoprodol, chlorzoxazone cyclobenzaprine, and orphenadrine are approved to treat muscle spasm. 

Browse the full report description Global Muscle Relaxant Drug Market Size, Share & Trends Analysis Report by Product Type (Peripherally Acting Muscle Relaxants, Facial Aesthetic Relaxants, and Centrally Acting Muscle Relaxants), by Formulation (Oral and Injectable), Forecast 2020-2026 at https://www.omrglobal.com/industry-reports/muscle-relaxant-drug-market 

Further, the key players operating in the global muscle relaxant drug industry is driving the market growth. Players such as AbbVie Inc., Acorda Therapeutics Inc., Cadila Healthcare Ltd., Dr. Reddy's Laboratories Ltd., Johnson & Johnson Services Inc., Merck & Co. Inc., Mylan NV, Orient Pharma Co. Ltd., Par Pharmaceutical Inc., and Pfizer Inc. are significantly contributing to the muscle relaxant drug market growth by adopting various growth strategies. Product launches & developments, partnerships, agreements, and acquisitions are among some of the strategies adopted by the players to sustain in a competitive muscle relaxant drug market during the forecast period. 

In September 2017, Dr. Reddy's Laboratories Ltd. launched the anti-depressant muscle relaxant tablet in the US. The company launched Bupropion Hydrochloride extended-release tablets for treating depressive disorder along with the launch of Metaxalone tablets to affluence the discomforts associated with acute, painful musculoskeletal conditions. 

In June 2017, Ipsen Biopharmaceuticals Inc. entered into a three-year agreement with Saol Therapeutics Inc. for the promotion and marketing of Dysport (abobotulinumtoxinA) for injection for approved therapeutic indications in adult spasticity and pediatric lower limb spasticity in the US.

In March 2017, the US FDA approved Cadila Healthcare Ltd. or Zydus Cadila for the marketing of tizanidine hydrochloride capsules, a muscle relaxant, in the US market.

Current Market Trends Covered in the market report:

• Increased investments by the companies to leverage the customers with a wide range of drugs is positively affecting the muscle relaxant drug market growth during the forecast period
• North America region will contribute a significant share in the market
• Novel drug development and innovations are expected to be the key strategies adopted by the key players to gain a competitive edge in the global muscle relaxant drug industry across the globe

Global Muscle Relaxant Drug Market – Segmentation

By Product Type 

• Peripherally Acting Muscle Relaxants
• Facial Aesthetic Relaxants
• Centrally Acting Muscle Relaxants 

By Formulation

• Oral
• Injectable

Global Muscle Relaxant Drug Market – Segmentation by Region